PF-Atlas › Clinical Trials › NCT05185089
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
Orvepitant Maleate · Phase 2
Registry ID
NCT05185089
Phase
Phase 2
Status
Completed
Drug / intervention
Orvepitant Maleate
Sponsor
Nerre Therapeutics Ltd.
Start
2022-08-01
Enrollment
80
Locations
37
About this trial
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05185089 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.